Dominari (DOMH) Revenue & Revenue Breakdown
Dominari Revenue Highlights
Latest Revenue (Y)
$2.04M
Latest Revenue (Q)
$4.04M
Dominari Revenue by Period
Dominari Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.04M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $9.00K | -67.86% |
| 2018-12-31 | $28.00K | -97.73% |
| 2017-12-31 | $1.24M | 40.94% |
| 2016-12-31 | $877.00K | 2557.58% |
| 2015-12-31 | $33.00K | 230.00% |
| 2014-12-31 | $10.00K | -62.96% |
| 2013-12-31 | $27.00K | 35.53% |
| 2012-12-31 | $19.92K | -97.57% |
| 2011-12-31 | $820.92K | -42.69% |
| 2010-12-31 | $1.43M | 5.40% |
| 2009-12-31 | $1.36M | 32.47% |
| 2008-12-31 | $1.03M | 563.20% |
| 2007-12-31 | $154.70K | -99.38% |
| 2006-12-31 | $24.84M | 7.78% |
| 2005-12-31 | $23.05M | 3.12% |
| 2004-12-31 | $22.35M | 23.56% |
| 2003-12-31 | $18.09M | 19.53% |
| 2002-12-31 | $15.13M | -24.10% |
| 2001-12-31 | $19.94M | 17.04% |
| 2000-12-31 | $17.03M | 34.13% |
| 1999-12-31 | $12.70M | -20.63% |
| 1998-12-31 | $16.00M | 17.65% |
| 1997-12-31 | $13.60M | -1.45% |
| 1996-12-31 | $13.80M | 0.73% |
| 1995-12-31 | $13.70M | -14.38% |
| 1994-12-31 | $16.00M | 17.65% |
| 1993-12-31 | $13.60M | - |
Dominari generated $2.04M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 7282.14% compared to the same period a year ago.
Dominari Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $4.04M | -34.52% |
| 2024-06-30 | $6.17M | 351.65% |
| 2024-03-31 | $1.37M | 36.02% |
| 2023-12-31 | $1.00M | 4.36% |
| 2023-09-30 | $963.00K | 1256.34% |
| 2023-06-30 | $71.00K | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $9.00K | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $28.00K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $284.00K | -9.55% |
| 2017-09-30 | $314.00K | 0.96% |
| 2017-06-30 | $311.00K | -4.89% |
| 2017-03-31 | $327.00K | 4.14% |
| 2016-12-31 | $314.00K | - |
| 2016-09-30 | $314.00K | 77.40% |
| 2016-06-30 | $177.00K | 145.83% |
| 2016-03-31 | $72.00K | 132.26% |
| 2015-12-31 | $31.00K | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | -100.00% |
| 2015-03-31 | $2.00K | 100.00% |
| 2014-12-31 | $1.00K | -50.00% |
| 2014-09-30 | $2.00K | -33.33% |
| 2014-06-30 | $3.00K | -25.00% |
| 2014-03-31 | $4.00K | -79.15% |
| 2013-12-31 | $19.19K | 944.58% |
| 2013-09-30 | $1.84K | 762.44% |
| 2013-06-30 | $213.00 | -96.30% |
| 2013-03-31 | $5.76K | -100.98% |
| 2012-12-31 | $-590.04K | -403.68% |
| 2012-09-30 | $194.30K | -5.73% |
| 2012-06-30 | $206.10K | -1.65% |
| 2012-03-31 | $209.56K | 61.07% |
| 2011-12-31 | $130.11K | -34.44% |
| 2011-09-30 | $198.46K | 6.67% |
| 2011-06-30 | $186.05K | -39.26% |
| 2011-03-31 | $306.30K | -24.22% |
| 2010-12-31 | $404.18K | 9.58% |
| 2010-09-30 | $368.84K | 12.75% |
| 2010-06-30 | $327.14K | -1.55% |
| 2010-03-31 | $332.29K | 15.45% |
| 2009-12-31 | $287.83K | -23.93% |
| 2009-09-30 | $378.37K | 13.88% |
| 2009-06-30 | $332.24K | -7.88% |
| 2009-03-31 | $360.67K | 15.53% |
| 2008-12-31 | $312.19K | 1.45% |
| 2008-09-30 | $307.71K | 16.93% |
| 2008-06-30 | $263.15K | - |
Dominari generated $4.04M in revenue during Q3 2024, up -34.52% compared to the previous quarter, and up 5694.37% compared to the same period a year ago.
Dominari Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $33.43M |
| SPRO | Spero Therapeutics | $96.73M | $13.47M |
| FRTX | Fresh Tracks Therapeutics | $8.01M | - |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.14M |
| ASMB | Assembly Biosciences | $7.16M | $6.84M |
| SNTI | Senti Biosciences | $2.56M | - |
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| DOMH | Dominari | $2.04M | $4.04M |
| MNOV | MediciNova | $1.00M | - |
| NXTC | NextCure | - | - |
| TIL | Instil Bio | - | - |
| HILS | Tharimmune | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| KTTA | Pasithea Therapeutics | - | - |